Focal adhesion kinase 1 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Focal adhesion kinase 1 shows late clinical disease relevance led by ovarian cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q05397. Start with ovarian cancer, then reuse UniProt Q05397 as the stable protein anchor across project notes and exports.
Start with ovarian cancer, then reuse UniProt Q05397 as the stable protein anchor across project notes and exports.
Focal adhesion kinase 1 shows late clinical disease relevance led by ovarian cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with ovarian cancer because it currently carries late clinical support. Linked drugs include DEFACTINIB, IFEBEMTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyFocal adhesion kinase 1
Review this target as Focal adhesion kinase 1, mapped to UniProt Q05397. Sequence length is 1052 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Focal adhesion kinase 1 as ChEMBL target CHEMBL2695, mapped to UniProt Q05397. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Focal adhesion kinase 1 is the right protein anchor across sources, using UniProt Q05397 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why ovarian cancer is currently framed as late clinical support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Focal adhesion kinase 1 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q05397 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Focal adhesion kinase 1 |
| UniProt Accession | Q05397 |
| Component Type | Protein |
| Sequence Length | 1052 aa |
Focal adhesion kinase 1
Review this target as Focal adhesion kinase 1, mapped to UniProt Q05397. Sequence length is 1052 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Focal adhesion kinase 1 shows late clinical disease relevance led by ovarian cancer. 5 more disease programs remain visible in the same review block.
Start review with ovarian cancer because it currently carries late clinical support. Linked drugs include DEFACTINIB, IFEBEMTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4554455 | 10.15 | IC50 | 0.07 | Preclinical |
| CHEMBL5170906 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL5198068 | 9.97 | IC50 | 0.1076 | Preclinical |
| CHEMBL5196177 | 9.93 | IC50 | 0.1165 | Preclinical |
| CHEMBL5176233 | 9.91 | IC50 | 0.1242 | Preclinical |
| CHEMBL5206909 | 9.81 | IC50 | 0.1534 | Preclinical |
| CHEMBL5187385 | 9.79 | IC50 | 0.161 | Preclinical |
| CHEMBL5190968 | 9.72 | IC50 | 0.1924 | Preclinical |
| CHEMBL5177776 | 9.71 | IC50 | 0.1941 | Preclinical |
| CHEMBL3137331 | 9.7 | IC50 | 0.2 | Clinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 502 | 1,426 | 6.7 |
| cell-based format | 218 | 179 | 7.7 |
| assay format | 74 | 408 | 8.3 |
| subcellular format | 27 | 24 | 6.6 |
| tissue-based format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 174 | 6.0 |